Synthetic oligonucleotides: the development of antisense therapeutics.

  title={Synthetic oligonucleotides: the development of antisense therapeutics.},
  author={David K B Monteith and Arthur A. Levin},
  journal={Toxicologic pathology},
  volume={27 1},
Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases. These macromolecules afford a unique opportunity to treat disease at the molecular level. The specificity of these compounds is derived from the genetic code and Watson-Crick base pairing, utilizing an antisense paradigm for the inhibition of translation and the regulation of protein expression. Currently, most antisense ODNs in… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 20 extracted citations

A status report on RNAi therapeutics

View 8 Excerpts
Highly Influenced

CpG Oligodeoxynucleotides as TLR9 Agonists

View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…